公开(公告)号：US20240262833A1

公开(公告)日：2024-08-08

申请号：US18559951

申请日：2022-05-13

Applicant: Addex Pharma S.A.

Inventor： Jean-Laurent Paparin ,  Jean-Philippe Rocher ,  Terry Finn ,  Guillaume Duvey

IPC: C07D487/04 ,  A61K31/5025 ,  A61K31/506

CPC classification number: C07D487/04 ,  A61K31/5025 ,  A61K31/506

Abstract: The present invention relates to novel compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.

公开(公告)号：US20240327375A1

公开(公告)日：2024-10-03

申请号：US18560011

申请日：2022-05-13

Applicant: Addex Pharma S.A.

Inventor： Jean-Laurent Paparin ,  Jean-Philippe Rocher ,  Patrick Mäder ,  Tanja Stach ,  Guillaume Duvey ,  Lam Tang

IPC: C07D401/04 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  C07D237/32 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D491/107 ,  C07D498/08

CPC classification number: C07D401/04 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  C07D237/32 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/04 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention relates to novel compounds of Formula (I), wherein A, m, Q, R1, R2, R3, R4 and R5 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.

公开(公告)号：US20140349994A1

公开(公告)日：2014-11-27

申请号：US14372986

申请日：2013-01-18

Applicant: Addex Pharma S.A.

Inventor： Christelle Bolea ,  Cedric Boudou ,  Sylvain Celanire ,  Vincent Darmency ,  Celine Mordant ,  Vincent Pericolle ,  Yannick Regereau ,  Jean-Philippe Rocher ,  Radouane Souissi ,  Lam Tang

IPC: C07D513/14 ,  A23L1/30 ,  A23L1/226 ,  A23L2/56 ,  A61K31/55 ,  A61K45/06

CPC classification number: C07D513/14 ,  A23L2/56 ,  A23L27/2056 ,  A23L33/10 ,  A61K31/55 ,  A61K45/06 ,  C07D513/04

Abstract: The present invention relates to novel compounds of Formula (I), wherein M and R1 are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

Abstract translation: 本发明涉及新的式（I）化合物，其中M和R 1如式（I）所定义; 本发明化合物是代谢型谷氨酸受体的调节剂 - 亚型4（“mGluR4”），其可用于治疗或预防中枢神经系统疾病以及由mGluR4受体调节的其它障碍。 本发明还涉及药物组合物和这些化合物在制备药物中的用途，以及这些化合物用于预防和治疗涉及mGluR4的疾病的用途。